We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Mylan, J&J In Authorized Generics Deal Over Ditropan XL

Law360 (December 20, 2005, 12:00 AM EST) -- Generic drug maker Mylan Laboratories and Johnson & Johnson subsidiary Alza have entered into an agreement over the rights to market a generic version of overactive bladder treatment Ditropan XL, adding more fuel to the fiery debate over authorized generics.

Under the agreement, Alza will supply Mylan with a generic form of Ditropan as soon as the patent litigation pending between the two companies over the drug is settled.

If another drug maker seeks to market Ditropan, Alza will begin supplying Mylan with the generic before...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.